• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Streamex Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    3/20/26 5:03:08 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STEX alert in real time by email
    false 0001530766 0001530766 2026-03-16 2026-03-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    March 16, 2026

    Date of Report (Date of earliest event reported)

     

    STREAMEX CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38659   26-4333375
    (State   (Commission   (I.R.S. Employer
    of incorporation)   File Number)   Identification Number)

     

    2431 Aloma Avenue, Suite 243

    Winter Park, Florida 32792

    (Address of principal executive offices) (Zip code)

     

    (203) 409-5444

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   STEX   The NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Resignation of Chief Financial Officer

     

    On March 20, 2026, Streamex Corp. (the “Company”) and Ferdinand Groenewald, who served as Chief Financial Officer, principal accounting officer and principal financial officer of the Company, entered into a Separation and General Release Agreement (“Separation Agreement”), in connection with Mr. Groenewald resignation from such roles, effective as of March 15, 2026 (the “Separation Date”). Mr. Groenewald’s resignation did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

     

    Pursuant to the Separation Agreement, and subject to the conditions set forth therein, Mr. Groenewald will be entitled to (i) cash severance payments in an amount equal to 6 months of Mr. Groenewald’s base salary, or $112,500, payable in accordance with the Company’s regular payroll schedule commencing on the first payroll date following the Effective Date (as defined in the Separation Agreement), (ii) a pro-rata portion of Mr. Groenewald’s annual bonus for the 2025 calendar year, payable in a lump sum cash payment no later than ten business days following the Effective Date, or, if later, the date 2025 annual bonuses are paid to other senior executives of the Company; provided that, Mr. Groenewald will not be entitled to such amounts to the extent such annual bonuses are not paid to other senior executives of the Company, (ii) a pro-rata portion of Mr. Groenewald’s target annual bonus for the 2026 calendar year, payable in a lump sum cash payment at the same time as annual bonuses are paid to other senior executives of the Company, but in no event later than March 15, 2027; provided that, Mr. Groenewald will not be entitled to such amounts to the extent such annual bonuses are not paid to other senior executives of the Company and (iii) reimbursement for continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA), as amended, for a period of up to twelve (12) months, with payments to be made within 30 days of the submission of reasonable relevant documentation.

     

    In connection with the Separation Agreement, the parties agreed to amend Mr. Groenewald’s outstanding restricted stock unit (“RSU”) award, originally consisting of 500,000 RSUs granted on January 8, 2026 under the Company’s 2023 Equity Incentive Plan (the “RSU Award”), to reduce the number of RSUs subject to such RSU Award to 301,500 RSUs, with all RSUs in excess of 301,500 being cancelled and of no further force or effect. Effective as of the Separation Date, 100% of the 301,500 RSUs subject to the amended RSU Award, together with 60,000 shares of restricted stock granted on November 18, 2025, that were originally scheduled to vest in full on November 18, 2026, became fully vested and subject to taxation and applicable withholdings on the Separation Date.

     

    Further, Mr. Groenewald has incurred certain tax liabilities prior to the Separation Date arising from certain awards of restricted shares of common stock, par value $0.001 per share (“Common Stock”), of the Company, which the Company has agreed to satisfy subject to the terms of the Separation Agreement. Pursuant to the Separation Agreement, Mr. Groenewald also agreed that any shares of the Company’s Common Stock held by Mr. Groenewald will be subject to a lock-up period of six months following the Separation Date, subject to certain exceptions.

     

    In addition, on March 16, 2026, the Company agreed to engage Groenewald Enterprises LLC (“Consultant”), an affiliate of Mr. Groenewald, as a consultant to the Company for a period of six months, commencing on March 16, 2026, pursuant to a consulting agreement (the “Consulting Agreement”), pursuant to which, Mr. Groenewald will perform certain services as an independent contractor to the Company, including financial reporting, SEC compliance, transition and general advisory consulting services (the “Services”) which such Services will primarily be performed through Mr. Groenewald. In consideration of the Services, the Company agreed to pay the Consultant a consulting fee of $20,000 per month. The Consulting Agreement may be terminated by either party upon 15 days’ written notice to the other party and the Company may terminate for Cause (as defined in the Consulting Agreement) immediately pursuant to the terms set forth therein. The Consulting Agreement also contains customary provisions regarding confidentiality, intellectual property assignment, non-solicitation of employees, mutual indemnification, and limitation of liability.

     

    In exchange for the consideration provided to Mr. Groenewald in the Separation Agreement, Mr. Groenewald agreed to waive and release any claims in connection with Mr. Groenewald’s employment and separation from the Company. In connection with the execution of the Separation Agreement, Mr. Groenewald’s existing employment agreement was terminated; provided, however, that certain surviving customary confidentiality provisions and restrictive covenants remain in full force and effect. The Separation Agreement also provides for certain customary covenants regarding confidentiality.

     

    The descriptions of the terms of the Separation Agreement and the Consulting Agreement contained in this Item 5.02 are qualified in its entirety by reference to the full text of the Separation Agreement and Consulting Agreement, a copy of which is attached hereto as Exhibit 10.1 and Exhibit 10.2, respectively, and are incorporated herein by reference.

     

     
     

     

    Appointment of Chief Financial Officer

     

    The Company appointed Christine Plummer to the position of Chief Financial Officer, principal accounting officer and principal financial officer, effective upon the resignation of Mr. Groenewald.

     

    Ms. Plummer, age 54, brings more than 30 years of experience leading global controllership, regulatory reporting, and finance transformation across the financial services and fintech sectors. Most recently, Ms. Plummer served as Global Controller at Coinbase, Inc. (“Coinbase”) from May 2025 until March 2026, where she led a global controllership organization of more than 50 professionals responsible for financial close, regulatory reporting, and operational readiness for new products. Prior to joining Coinbase, Ms. Plummer served as Global Deputy Controller and Managing Director at MSCI Inc. from 2022 to 2025, where she led the Global Commercial Revenue Controllership team of more than 70 professionals across multiple international locations. She also served as Interim Global Controller supporting the Chief Financial Officer upon the departure of the Chief Accounting Officer, providing oversight for SEC Reporting, Accounting Policy, and SOX Control teams. Earlier in her career, Ms. Plummer spent more than two decades at Morgan Stanley, where she held a series of senior leadership roles, including Chief Financial Officer and Managing Director for Americas Legal Entities from 2019 to 2022, Global Head of Funding Controllers and Managing Director from 2012 to 2019, and Global Product Controller and Executive Director for the Equity Division from 2008 to 2012. In these roles, she led large global teams, implemented complex regulatory frameworks including SEC and CFTC Swap Dealer Rules, supported critical capital and liquidity management initiatives, and built large, multi-location finance organizations supporting the firm’s global operations. Ms. Plummer began her career as an auditor at Ernst & Young. Ms. Plummer holds a Bachelor of Science in Finance and Accounting from Cornell University and is a Certified Public Accountant and holds Series 27 and Series 99 licenses.

     

    There is no arrangement or understanding between Ms. Plummer and any other person pursuant to which Ms. Plummer was appointed as an executive officer of the Company. There are no family relationships between Ms. Plummer and any director or executive officer of the Company that would be required to be disclosed pursuant to Item 401(d) of Regulation S-K, and there are no transactions involving Ms. Plummer that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.

     

    In connection with Ms. Plummer’s appointment, the Company entered into an Employment Agreement with Ms. Plummer, dated as of March 16, 2026 (the “Employment Agreement”).

     

    Under the Employment Agreement, Ms. Plummer will receive an annual base salary of $350,000, payable in equal semi-monthly installments in arrears. Ms. Plummer will also be eligible to receive an annual discretionary bonus based on Ms. Plummer’s achievement on the performance of the balance sheet portfolio and individual performance goals established by the Company and Ms. Plummer at the start of the relevant year. In addition, subject to approval by the Compensation Committee of the Company, Ms. Plummer will be entitled to receive a grant of 500,000 restricted stock units (the “2026 RSU Award”), which will vest quarterly over 48 months, subject to approval by the Compensation Committee.

     

    In the event of a termination of Ms. Plummer without Cause (as defined in the Employment Agreement) or a resignation for Good Reason (as defined in the Employment Agreement), Ms. Plummer will be entitled to the following severance benefits: (i) six months of Ms. Plummer’s then in-effect base salary; (ii) six months of continued health, dental and vision coverage; (iii) a prorated annual bonus for the year of termination based on actual performance; and (iv) full accelerated vesting of all unvested and outstanding RSUs.

     

    Upon a Change in Control (as defined in the Employment Agreement), the RSUs subject to the 2026 RSU Award will become fully vested. In addition, if a Change in Control occurs prior to payment of an annual bonus for any fiscal year, such annual bonus will become payable upon the occurrence of the Change in Control.

     

    The Employment Agreement also contains customary restrictive covenants, including that during Ms. Plummer’s employment and for a period of 12 months following termination, Ms. Plummer is subject to (i) non-competition restrictions prohibiting her from engaging in activities in connection with profit-seeking or business reasons utilizing blockchain or cryptocurrency technology for the tokenization of commodities, interests in commodities (including derivatives thereon, royalty streams, or other interests), securities, real estate, or other goods or services until 12 months following termination, and (ii) non-solicitation restrictions prohibiting her from soliciting the Company’s customers, business relations, employees or contractors.

     

     
     

     

    Ms. Plummer is also eligible to receive additional annual equity compensation, the amount and form of which will be determined by the Compensation Committee in accordance with the Company’s equity compensation policies. The Company will provide Ms. Plummer with the same indemnification rights afforded to its other officers under its governing documents and applicable law, including the advancement of expenses to the fullest extent permitted. Additionally, the Company will maintain directors and officers liability insurance covering Ms. Plummer in her capacity as an officer, on terms no less favorable than those applicable to other senior officers of the Company. Such coverage will remain in effect for the duration of Ms. Plummer’s term of service and for any applicable tail period following her departure, as required by law or Company policy.

     

    The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.3.

     

    Item 8.01 Other Events.

     

    On March 16, 2026, the Company issued a press release announcing the appointment of Ms. Plummer as Chief Financial Officer of the Company.

     

    A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit
    Number
      Description
    10.1   Separation and General Release Agreement, dated March 20, 2026.
    10.2   Consulting Agreement, dated as of March 20, 2026, by and between the Company and Groenewald Enterprises LLC.
    10.3   Employment Agreement, dated March 16, 2026, by and between the Company and Christine Plummer.
    99.1   Press Release, dated March 16, 2026
    104   Cover Page Interactive Data File (formatted as Inline XBRL)

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: March 20, 2026 By: /s/ Karl Henry McPhie
      Name: Karl Henry McPhie
      Title: Chief Executive Officer

     

     

    Get the next $STEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STEX

    DatePrice TargetRatingAnalyst
    11/25/2025$12.00Buy
    Needham
    More analyst ratings

    $STEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Streamex Corp. to Present at the 38th Annual ROTH Conference

    WINTER PARK, Fla., March 19, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology and infrastructure company focused on the tokenization of commodity real-world assets, today announced Morgan Lekstrom, Co-Founder and Executive Chairman, and Russell Starr, Head of Capital Markets, will present at the 38th Annual ROTH Conference in Dana Point, California. The management team will present on a panel discussion titled The Future of Finance - Bridging DeFi and TradFi for Scaled Adoption. As institutional interest in digital assets reaches an inflection point, Streamex's management team will outline how the Company is positioning its technology to mo

    3/19/26 8:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Appoints Christine Plummer, Former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer

    WINTER PARK, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology and infrastructure company focused on the tokenization of commodity real-world assets, today announced the appointment of Christine Plummer, former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer of Streamex. In this role, Ms. Plummer is expected to oversee the Company's global finance organization, including financial reporting, regulatory compliance, and financial operations as Streamex continues expanding its institutional platform and launching tokenized commodity products. Henry McPhie, Co-Founder & CEO of Str

    3/16/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Appoints Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. & Founder and CIO of Hondius Capital Management, to Board of Directors

    WINTER PARK, Fla., March 03, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today is excited to announce the appointment of Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. and Founder and Chief Investment Officer of Hondius Capital Management, to its Board of Directors. In this role, Mr. Matthews will bring decades of global investment, trading, and executive leadership experience to support Streamex's strategic growth, capital markets initiatives, and governance. He is joining as an independent director. Morgan Lekstrom, Co-Founder & Executive Chairman of Streamex sa

    3/3/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Streamex Exchange Corporation with a new price target

    Needham initiated coverage of Streamex Exchange Corporation with a rating of Buy and set a new price target of $12.00

    11/25/25 7:59:34 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    SEC Filings

    View All

    Streamex Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    3/20/26 5:03:08 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    3/6/26 4:01:51 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    2/13/26 5:09:54 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Matthews Shawn claimed ownership of 100,000 shares (SEC Form 3)

    3 - Streamex Corp. (0001530766) (Issuer)

    3/9/26 4:01:18 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Marciano Anthony Mark was granted 100,000 shares (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/24/26 6:07:38 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Executive Chairman Lekstrom Morgan Lee bought $50,000 worth of shares (20,000 units at $2.50) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/18/26 1:41:34 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Lekstrom Morgan Lee bought $50,000 worth of shares (20,000 units at $2.50) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/18/26 1:41:34 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Giustra Frank bought $317,000 worth of shares (100,000 units at $3.17) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/4/26 7:04:10 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Lekstrom Morgan Lee bought $71,910 worth of shares (23,500 units at $3.06) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/3/26 11:32:53 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Leadership Updates

    Live Leadership Updates

    View All

    Streamex Corp. Appoints Christine Plummer, Former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer

    WINTER PARK, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology and infrastructure company focused on the tokenization of commodity real-world assets, today announced the appointment of Christine Plummer, former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer of Streamex. In this role, Ms. Plummer is expected to oversee the Company's global finance organization, including financial reporting, regulatory compliance, and financial operations as Streamex continues expanding its institutional platform and launching tokenized commodity products. Henry McPhie, Co-Founder & CEO of Str

    3/16/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Appoints Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. & Founder and CIO of Hondius Capital Management, to Board of Directors

    WINTER PARK, Fla., March 03, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today is excited to announce the appointment of Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. and Founder and Chief Investment Officer of Hondius Capital Management, to its Board of Directors. In this role, Mr. Matthews will bring decades of global investment, trading, and executive leadership experience to support Streamex's strategic growth, capital markets initiatives, and governance. He is joining as an independent director. Morgan Lekstrom, Co-Founder & Executive Chairman of Streamex sa

    3/3/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Appoints Morgan Lekstrom as Executive Chairman, and Announces Completed Repayment of Convertible Debenture and Cancellation of SEPA

    WINTER PARK, Fla., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced that its Co-Founder and Chairman, Morgan Lekstrom, has been named Executive Chairman and will join the executive leadership team. The Company has also announced that the previously entered into Secured Convertible Debentures with YA II PN, LTD., a Cayman Islands exempt limited company ("Yorkville" or "Holder") have been fully repaid and the Standby Equity Purchase Agreement (the "SEPA") previously entered into with Yorkville has been cancelled. "I am honoured and excited to step int

    2/9/26 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Financials

    Live finance-specific insights

    View All

    Streamex Corp. (NASDAQ: STEX) Acquires 9.9% Strategic Equity Stake in Royalty and Streaming Firm Empress Royalty Corp. Through a Premium Priced Share-for-Share Transaction at US$5.00 STEX with a Leading Institutional Investment Firm

    LOS ANGELES, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and real-world asset infrastructure, today announced that it has acquired a 9.9% equity interest in Empress Royalty Corp. ("Empress") (TSXV:EMPR) through a strategic share purchase from Terra Capital Natural Resources Fund Pty Ltd. ("Terra Capital"), a prominent institutional investor. Under the executed Share Purchase Agreement, Streamex acquired 12,671,297 common shares of Empress in exchange for 2,443,750 restricted common shares of Streamex at a US$5.00 STEX share price, representing a premium to the current market price of STEX and an

    12/11/25 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Announces Launch of $100,000,000 USD GLDY Pre-Sale – A Gold-Backed Yield Generating Stablecoin Offering Institutional Yield on Physical Gold Bullion

    The launch of Streamex's $100 million USD GLDY pre-sale marks a historic opportunity for gold investors. Investing in gold is no longer just a static store of value, Streamex, through GLDY has created a yield-generating, institutional grade asset designed to offer both spot gold exposure and yield paid in additional ounces of physical gold bullion.  Key Highlights Gold Price Exposure and Gold-Denominated Distributions: GLDY is designed to combine audited physical bullion holdings with yield from institutionally managed gold leases sourced through Monetary Metals. GLDY seeks to provide exposure to the price of gold while targeting periodic distributions paid in additional ounces of gold.Rev

    11/10/25 8:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care